Overview
Altering the Cycle of Clostridium difficile Infection: Combining Standard-of-Care and Emerging Therapies to Prevent Recurrence
C. diff Clinical Commentary
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This HD video roundtable discussion will address available evidence for the management and prevention of recurrent Clostridium difficile infection (CDI), guideline recommendations, and investigational approaches.
This educational activity is designed for gastroenterologists, infectious disease specialists, and other healthcare professionals treating Clostridium difficile infections.
Clostridium difficile, a Gram-positive bacteria that causes diarrhea, abdominal bloating, and colitis, is associated with significant morbidity and mortality. Up to 25% of patients with an initial episode of C. difficile infection (CDI) experience disease recurrence. Recurrent CDI is particularly challenging to manage. Clinicians must be able to identify patients at high risk of recurrent CDI to ensure prompt recognition and treatment aimed at mitigating the risk of recurrence. Multiple agents, with varying mechanisms of action, are under investigation to manage and prevent CDI recurrence.
Upon completion of this activity, participants will be able to:
• Identify patients who may be at increased risk for recurrent C. diff infection
• Outline evidence-based approaches for the management of first, second, and third recurrences of C. diff in diverse patient populations
• Discuss investigational approaches to the management of recurrent C. diff
• Identify patients who may be at increased risk for recurrent C. diff infection
• Outline evidence-based approaches for the management of first, second, and third recurrences of C. diff in diverse patient populations
• Discuss investigational approaches to the management of recurrent C. diff
Sponsored by the Academy for Continued Healthcare Learning.
This activity is supported by an educational grant from Merck & Company.
Ciarán P. Kelly, MD (Chair)
Professor of Medicine
Harvard Medical School
Director, Gastroenterology Fellowship Training
Medical Director, Celiac Center
Beth Israel Deaconess Medical Center
Boston, MA
Paul Feuerstadt, MD, FACG
Gastroenterology Center of Connecticut
Clinical Instructor of Medicine
Yale University School of Medicine
Hamden, CT
Stuart Johnson, MD, FIDSA, DTM&H
Professor of Medicine, Infectious Disease
Loyola University Stritch School of Medicine
Staff Physician
Hines VA Hospital
Chicago, IL
Professor of Medicine
Harvard Medical School
Director, Gastroenterology Fellowship Training
Medical Director, Celiac Center
Beth Israel Deaconess Medical Center
Boston, MA
Paul Feuerstadt, MD, FACG
Gastroenterology Center of Connecticut
Clinical Instructor of Medicine
Yale University School of Medicine
Hamden, CT
Stuart Johnson, MD, FIDSA, DTM&H
Professor of Medicine, Infectious Disease
Loyola University Stritch School of Medicine
Staff Physician
Hines VA Hospital
Chicago, IL
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity. ACHL also requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CME/CE activity.
Paul Feuerstadt, MD, FACG Consultant: Medivators and Merck & CompanySpeakers’ Bureau: Entera Health and Merck & Company
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Clinicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
The following financial relationships have been provided:
Ciaran P. Kelly, MD
Consultant: Merck & Company, Seres Therapeutics, Summit Pharmaceuticals
Ciaran P. Kelly, MD
Consultant: Merck & Company, Seres Therapeutics, Summit Pharmaceuticals
Stuart Johnson, MD, FIDSA, DTM&H
Advisory Board: Bio-K Plus International Inc., Summit Therapeutics and Seres Therapeutics, Inc.
Barbara Lewis (Moderator)
Nothing to disclose
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Antimicrobials, immunotherapies, vaccines, and antibodies under investigation for CDI
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pre-assessment, view the online webcast, achieve at least 80% on the post-test and complete the evaluation form. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 203.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 203.
The Academy for Continued Healthcare Learning (ACHL) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
